Downloading...
Download

EDIT

EDITAS MEDICINE INC - EDIT - US EQUITIES TECHNICAL ANALYSISTicker: EDIT LAST= 26.20 EDITAS MEDICINE INC movement during the last few days showed a Sideways movement, with a recent low price seen on Mon 24.Dec.2018 at 17.80 The Short-Term view is expected to continue to be UP as long as the price is above 25.75, and it's recommended to ' BE LONG ' for a targeted price of around 29.40 Taking in consideration the resistance levels. On the other hand, a change in the direction of the general trend needs to be considered when the price trades below the level 22.88 Res_2 = 29.00 Res_1 = 26.65 Sup_1 = 24.30 Sup_2 = 21.95
NASDAQ:EDITLong
by EmadSaqqa
EDITAS MEDICINE INCSun 02/Dec/2018 Ticker: EDIT LAST= 31.16 EDITAS MEDICINE INC movement during the last few days showed a Bullish move, with a recent high price seen on Fri 30.Nov.2018 at 31.21. During the next few days the price is expected to go up for 31.21 and then to 32.40. The Short-Term view is expected to continue to be UP as long as the price is above 29.05. But as of now, as long as the price is trading above 28.75, its recommended to for a targeted price of around 33.70 Taking in consideration the resistance levels. On the other hand, a change in the direction of the general trend needs to be considered when the price trades below the level 27.35 Res_2 = 32.55 Res_1 = 31.38 Sup_1 = 30.21 Sup_2 = 29.04
NASDAQ:EDITLong
by EmadSaqqa
Long EDIT @ trendline supportA tight stop could be set here but I went with a bit looser one that would confirm a break down from trendline. Could be held long term or short. Good risk:reward. The topic of genesiology/eugenics may be ignored and considered morally reprehensible in modern society, but appears to be inevitable. I will ignore moral argument for this discussion. The film Gattaca presents a vision of a future society driven by eugenics where potential children are conceived through genetic selection to ensure they possess the best hereditary traits of their parents. NASA has named Gattaca as the most accurate science fiction film of all time. Selective genesiology is inevitable. This article reviews modern research aimed at making Gattaca the future. nerdist.com Some researches are quoted as saying genetic selection will be reality as soon as 5 years from now. Gender and eye color can already be selected for with a procedure known as pre-implantation genetic diagnosis (PGD). Key traits could include height and skin color. Susceptibility to cancer, heart disease, obesity, and genetic disease could also be on the table. Industries associated with these traits are already trillion dollar industries. Studies show height plays a major role in male social & financial success. Koreans and other asian culture pump millions into solutions to lighten their skin. Gene replacement and repair with enzyme complex CRISPR/Cas9 has already been successfully performed in human embryos but 100% success has not been achieved and embryos have not been allowed to gestate. This technology will likely be used to revolutionize the agriculture industry before human applications are practical. Stocks in this category are highly dependent on the success or failure of the CRISPR-Cas9 procedure, and as the limitations of the procedure become more clear, stock prices will suffer. Stocks NASDAQ: NTLA Intellia Therapeutics Inc is a research company deticated to in vivo gene modication. Risky bet, highly depedent on CRISPR-Cas9 procedure Market Cap: 1.2B P/E: -- No entry currently watch for move down to daily volume node NYSE:COO CooperSurgical is a business unit of The Cooper Companies, Inc., a global medical device company involved with IVF technologies Safe bet, dividends, earnings Market Cap: 11.2B P/E: 30 Entry available now with option for tight stop NASDAQ: EDIT Editas Medicine is a biotechnology firm with a mission of using gene editing to treat disease. Risky bet, highly depedent on CRISPR-Cas9 procedure Market cap: 1.8B P/E: -- CRSP Biotechnology start up company based on CRISPR-Cas9 genome editing Risky bet, highly depedent on CRISPR-Cas9 procedure Market cap: 3.2B P/E: -- ARKG ETF of genome companies (includes most of the above companies) Articles NASA has named Gattaca as the most accurate science fiction film of all time. www.theatlantic.com This article reviews modern research aimed at making Gattaca the future. nerdist.com Over 5,000,000 babies have been born using IVF assisted technologies (which can allow for selection of eye color and gender) www.livescience.com Gene replacement and repair with enzyme complex CRISPR/Cas9 Performed (this is the complex that allows for discovery of genes related to various diseases, even baldness, height, etc) www.nature.com CRISPR patent legal battle (update on ongoing legal battle between Editas Medicine (NASDAQ:EDIT) and CRISPR patent holder) www.scientificamerican.com Podcast about Gattaca,
NASDAQ:EDITLong
by autemox
NTLA sitting at 17.28 resistance, will it break thru or to 15s?NTLA has been flying through resistance levels from oversold conditions and looks like it's testing 17.28 resistance to establish it as support. If it closes above, likely going higher - if it rejects off of 17.28 then likely retest of high 15s before re-testing 17s. Apart from ongoing patent battles, this company was hit by a scientific paper that made unfounded claims against their gene editing tech CRSPR, which prompted a panic sell. Yet another paper discrediting the previous negative article was released today, which explains the ~6% jump. This is a super undervalued company with no debt. Either way, I sold some calls against part of my holding since they filed forms which suggest they may be planning a secondary. Waiting for a nice red day to sell more puts. Buy and hold long with co-CRSPR-patent holders EDIT & CRSP.
NASDAQ:NTLALong
by heidib
EDIT off the bounce on low volume.Nice support level at $20 Filled Gap up and Gap down. If decent trading volume, long term investors or proponents to CAS-9 research will buy in at these support levels. CRISPR got upgraded. EDITAS holds patents that relate to the use of CRISPR-Cas9 in the cells of humans and other eukaryotes, while the UC Berkeley, Crispr, patents cover use of the gene-editing approach more generally. Licensing plays from one company to the other. No profit in the near term. Bump in stock off Crispr viral news.
NASDAQ:EDITLong
by tonyyubc
EDIT - downward channel breakout Long trade from $25.21 to 31.37EDIT had a lovely flag setup. It continued further up and started to consolidating within a downward channel. Now it seems broken out the channel formation. We think it has good upside potential from here. * Trade Criteria * Date first found- March 13 Pattern/Why- Flag formation; Downward channel breakout Entry Target Criteria- Break of $25.21 Exit Target Criteria- $28.37; 2nd Target - $31.37 Stop Loss Criteria- $23.27 Please check back for Trade updates. (Note: Trade update is little delayed here.)
NASDAQ:EDITLong
by AcornWealthCorp
EDIT - Strong flag formation Long from $24 to $31.57EDIT looks like an awesome flag formation. We sent this out during Fridays Live trading session. It looks like a great flag from $24 and upward. * Trade Criteria * Date First Found- February 17, 2017 (In Live trading session) Pattern/Why- Strong flag potential Entry Target Criteria- Break of $24 or above Exit Target Criteria- $31.57 Stop Loss Criteria- $23.37 Please check back for Trade updates. (Note: Trade update is little delayed here.)
NASDAQ:EDITLong
by AcornWealthCorp